Tag Archives: pulmonary infection

PneumoNP: Exciting 6-month race ahead

With only six months to go before its end, the PneumoNP consortium gathered once more for their penultimate progress meeting on June 20-21, 2017 hosted in the beautiful city of Maastricht by project partner PathoFinder.

During the 1.5-day meeting, the consortium partners discussed the course for the last six months of the project’s duration. The primary goal to bear in mind: to reach the maximum outcome of the project!

Meeting in Maastricht

PneumoNP focuses on the development of a theragnostic system for the treatment of resistant Gram-negative bacterial infections in the lungs. For the treatment, a nanotherapeutic based inhalable antibiotic will be developed composed of a nanocarrier combined with an antimicrobial peptide. Based on the concentration of the drug in the lungs, level of toxicity side effects and the therapeutic efficacy of the nanoformulations used in pilot tests, the setup of the in vivo tests at Erasmus MC was fixed at the meeting.

PneumoNP’s consortium

PneumoNP’s consortium at its meeting in June 2017 in PathoFinder’s facilities

A visit to PathoFinder’s facilities rounded up the meeting. PathoFinder contributes to PneumoNP by improving the usage of antibiotics with the development of a diagnostic kit. The kit allows to identify antibiotic resistant strains of bacteria from a unique sample.

visite1

Right before its end, PneumoNP is happy to announce its 2nd workshop. It will take place within the scope of the Molecular Imaging Workshop (MIW2017) organised by PneumoNP partner CIC biomaGUNE on November 20-23, 2017 in San Sebastian, Spain. The MIW2017 offers the opportunity to discuss molecular imaging applications to neurosciences and oncology. PneumoNP will take part with a half-day workshop on November 23, 2017. Several partners from the project will present their work in PneumoNP in relation to imaging.

__________________________________________________________________

Read more PneumoNP news

cropped-Logo_PneumoNP_Simple_PRINT-01.png

Join the Molecular Imaging Workshop 2017

The second edition of the Molecular Imaging Workshop 2017 (MIW2017) will be held from 20th to 23rd November 2017 in San Sebastian, ...
Read More
ETP Nanomedicine is the European Forum aiming at developping, supporting and promoting the field of nanotechnologies applied to medicine.
ETP Nanomedicine translates business, clinical interface, toxicology and characterisation, education and training, ethics and social impact to pursue its goal. Indeed, the organisation intent is to enable diagnostics and imaging, therapy and targeted delivery, and regenerative medicine.

Meet us at the ETPN2017 event

PneumoNP partners will attend the ETPNanomedicine event in Malaga, Spain from 17th to 19th October 2017. The European Technology Platform on ...
Read More
FIGON Conference

Meet us at the FIGON Dutch Medicine Days

PneumoNP partners will attend FIGON Dutch Medicine Days in Ede, the Netherlands on 2nd and 3rd of October 2017. ...
Read More

A step forward towards therapeutic aerosols

A delivery device for a breathable drug has been prototyped to test a new drug formulation. It aims to fight respiratory tract infections.

To cure infections located in lungs, you can deliver antibiotic through the blood vessels or directly via the airways. Despite the many advantages of pulmonary delivery, few nebulization systems are designed.

The PneumoNP project develops an antibiotic formulation acting against drug resistant pneumonia. As it aimed for inhaled therapy, an aerosol system was chosen to deliver it. The Spanish company Ingeniatrics Technologías S.L. is in charge of prototyping the nebulizer device.

The Flow Blurring® nebulizer (©Ingeniatrics Technologías S.L.)

Picture 1: The Flow Blurring® nebulizer (©Ingeniatrics Technologías S.L.)

Setting up a nebulizer requires more than a random combination of compressed air and liquid. Indeed, the output needs to fulfill many conditions to be efficient.  Amongst others, the mist has to be breathable. So, droplets should be smaller than 3 μm to reach each corner of the lung. Achieving this result was especially challenging as the drug formulation contained large molecules.

Ingeniatrics used its technology called Flow Blurring® to produce the aerosol prototype. The Flow Blurring® relies on an atomisation technique that creates an ultra-fine mist from liquid; besides, it requires less energy compared to collision nebulizers. The microfluidic system produces turbulent mixing between a compressed air and the liquid drug. It yields droplets that are smaller than the output pipe. The system is versatile including, not only the proper fluid delivery accessories, but also the possibility to use mist chambers in combination with the Flow Blurring® technology.

illustration-scientifique-aerosol-v01-01

Picture 2: The Flow Blurring® technology adapted to drug delivery

As of today, the prototype is already in function. In the Dutch Erasmus Medical Center and in the Spanish CIC Biomagune laboratories, rats have been accustomed to the prototype setup. Now, researchers can look at the healing time of the rats when they inhale the drug. Initially designed for these in-vivo tests on rodents, the aerosol prototype has also been adapted to in-vitro investigations. In particular, researchers of the German Fraunhofer ITEM expose human epithelial lung cells to the therapeutic mist. They measure cytotoxicity and efficiency indices with this setup.

The aerosol delivery prototype will benefit from these users’ feedbacks for further refinement of the system. If the aerosol system is promising enough, it may become an industrial medical device for human or animal use.

__________________________________________________________________

Learn more on Ingeniatrics’ activities

__________________________________________________________________

Read more PneumoNP news

cropped-Logo_PneumoNP_Simple_PRINT-01.png

Join the Molecular Imaging Workshop 2017

The second edition of the Molecular Imaging Workshop 2017 (MIW2017) will be held from 20th to 23rd November 2017 in San Sebastian, ...
Read More
ETP Nanomedicine is the European Forum aiming at developping, supporting and promoting the field of nanotechnologies applied to medicine.
ETP Nanomedicine translates business, clinical interface, toxicology and characterisation, education and training, ethics and social impact to pursue its goal. Indeed, the organisation intent is to enable diagnostics and imaging, therapy and targeted delivery, and regenerative medicine.

Meet us at the ETPN2017 event

PneumoNP partners will attend the ETPNanomedicine event in Malaga, Spain from 17th to 19th October 2017. The European Technology Platform on ...
Read More
FIGON Conference

Meet us at the FIGON Dutch Medicine Days

PneumoNP partners will attend FIGON Dutch Medicine Days in Ede, the Netherlands on 2nd and 3rd of October 2017. ...
Read More

M33, the new option to fight severe pneumonia

The antimicrobial peptide M33 may be the long-sought substitute to treat difficult lung infections, like multi-drug resistant pneumonia.

In 2013, the European Respiratory Society predicted 3 millions cases of pneumonia in Europe every year[1]. The standard treatment for pneumonia is an intravenous administration of a combination of drugs. This leads to the development of antibiotic resistance in the population. Gradually, doctors are running out of solutions to cure patients. An Italian company suggests a new option: the M33 peptide.

Few years ago, the Italian company SetLance SRL decided to investigate the M33 peptide. The antimicrobial peptide is an optimized version of an artificial peptide sequence selected for its efficacy and stability. So far, it showed encouraging in-vitro results against multidrug-resistant Gram-negative bacteria, including Klebsiella Pneumoniae. With the support of EU funding to the PneumoNP project, SetLance SRL had the opportunity to develop a new formulation of M33 that enhances its antimicrobial activity.

Action of a M33 peptide on the membrane of a gram-negative bacteria

Fig. Action of a M33 peptide on the membrane of a gram-negative bacteria

 

The new formulation of M33 fights Gram-negative bacteria in three steps. First of all, the M33 binds with the lipopolysaccharides (LPS) on the outer membrane of bacteria. Then, the molecule forms a helix and finally disrupts the membrane provoking cytoplasm leaking. The peptide enabled up to 80% of mice to survive Pseudomonas Aeruginosa-based lung infections. Beyond these encouraging results, toxicity to the new M33 formulation seems to be much lower than antimicrobial peptides currently used in clinical practice like colistin[2].

Lately, SetLance scaled-up the synthesis route and is now able to produce several hundred milligrams per batch. The molecule is robust enough for industrial production. We may expect this drug to go on clinical development and validation at the beginning of 2018.

____________________

[1] http://www.erswhitebook.org/chapters/acute-lower-respiratory-infections/pneumonia/

[2] Ceccherini et al., Antimicrobial activity of levofloxacin-M33 peptide conjugation or combination, Chem Med Comm. 2016;
Brunetti et al., In vitro and in vivo efficacy, toxicity, bio-distribution and resistance selection of a novel antibacterial drug candidate. Scientific Reports 2016

 

__________________________________________________________________

Read more articles on PneumoNP activities

cropped-Logo_PneumoNP_Simple_PRINT-01.png

Join the Molecular Imaging Workshop 2017

The second edition of the Molecular Imaging Workshop 2017 (MIW2017) will be held from 20th to 23rd November 2017 in San Sebastian, ...
Read More
ETP Nanomedicine is the European Forum aiming at developping, supporting and promoting the field of nanotechnologies applied to medicine.
ETP Nanomedicine translates business, clinical interface, toxicology and characterisation, education and training, ethics and social impact to pursue its goal. Indeed, the organisation intent is to enable diagnostics and imaging, therapy and targeted delivery, and regenerative medicine.

Meet us at the ETPN2017 event

PneumoNP partners will attend the ETPNanomedicine event in Malaga, Spain from 17th to 19th October 2017. The European Technology Platform on ...
Read More
FIGON Conference

Meet us at the FIGON Dutch Medicine Days

PneumoNP partners will attend FIGON Dutch Medicine Days in Ede, the Netherlands on 2nd and 3rd of October 2017. ...
Read More

Heal pulmonary infections with nanosystems

Fine nanosystems carrying Meropenem and antimicrobial peptides to fight pulmonary infections are ready for in vitro tests.

Before 2016 starts, the PneumoNP project reaches an important milestone towards the development of an inhalable nanotechnology-based drug for the treatment of lung infections: the generation of promising nanosystems allowing pulmonary delivery. For the last 2 years, researchers from Denmark, Germany, Italy, the Netherlands and Spain have joined efforts to synthesize nanocarriers (single chain nanoparticles and liposomes) and effective antimicrobial peptides (AMPs). They combine them together into versatile antibiotic-carrying nanosystems, and verify their biocompatibility in vitro as well as their efficacy against selected strains of Klebsiella pneumoniae.

Scheme of nanosystems by PneumoNP

Among the challenges, nanosystems had to be prepared in such a way to maintain the AMPs’ therapeutic effect and to allow aerosol delivery. Different inhalable nanosystems have been developed that fulfil these requirements. The new nanosystems designed by PneumoNP scientists and the non-invasive administration will allow a focused action on pulmonary infections.

The avoidance of first-pass metabolism and the improved cellular internalization will enhance the therapeutic efficiency of drugs, decreasing the risk of patients suffering from potential side effects. The nanocarriers could also play a significant role in improving the stability of AMPs towards degradation in vivo and in increasing their permanence in the lungs. Last but not least, nanosystems can also carry imaging agents that can increase the diagnostic accuracy and sensitivity of disease detection.

The next step for the PneumoNP project is to test the selected nanosystems in vivo, a step that should be finished by the end of 2017.

__________________________________________________________________

Read more PneumoNP news

cropped-Logo_PneumoNP_Simple_PRINT-01.png

Join the Molecular Imaging Workshop 2017

The second edition of the Molecular Imaging Workshop 2017 (MIW2017) will be held from 20th to 23rd November 2017 in San Sebastian, ...
Read More
ETP Nanomedicine is the European Forum aiming at developping, supporting and promoting the field of nanotechnologies applied to medicine.
ETP Nanomedicine translates business, clinical interface, toxicology and characterisation, education and training, ethics and social impact to pursue its goal. Indeed, the organisation intent is to enable diagnostics and imaging, therapy and targeted delivery, and regenerative medicine.

Meet us at the ETPN2017 event

PneumoNP partners will attend the ETPNanomedicine event in Malaga, Spain from 17th to 19th October 2017. The European Technology Platform on ...
Read More
FIGON Conference

Meet us at the FIGON Dutch Medicine Days

PneumoNP partners will attend FIGON Dutch Medicine Days in Ede, the Netherlands on 2nd and 3rd of October 2017. ...
Read More